Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) saw unusually-high trading volume on Tuesday . Approximately 789,511 shares were traded during trading, an increase of 60% from the previous session’s volume of 494,557 shares.The stock last traded at $4.44 and had previously closed at $3.92.

The stock’s market cap is $287.45 million. The firm has a 50-day moving average price of $3.58 and a 200 day moving average price of $4.31.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by $0.08. The firm had revenue of $12.60 million for the quarter, compared to the consensus estimate of $9.70 million. The firm’s quarterly revenue was up 142.3% on a year-over-year basis. Equities analysts anticipate that Aralez Pharmaceuticals Inc. will post ($1.00) EPS for the current year.

In related news, CFO Scott J. Charles acquired 50,000 shares of the stock in a transaction that occurred on Thursday, May 12th. The stock was acquired at an average cost of $3.49 per share, for a total transaction of $174,500.00. Following the transaction, the chief financial officer now directly owns 213,368 shares in the company, valued at $744,654.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Andrew I. Koven acquired 71,500 shares of the stock in a transaction that occurred on Thursday, May 12th. The shares were bought at an average price of $3.49 per share, with a total value of $249,535.00. Following the completion of the transaction, the insider now owns 1,610,306 shares in the company, valued at $5,619,967.94. The disclosure for this purchase can be found here.

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.